Webinar

Primary Human Microphysiological Systems for Testing HSD17B13 Inhibitors

Now Available On Demand

Non-alcoholic steatohepatitis (NASH) is a highly prevalent disease, currently unmet therapeutically. NASH is characterized by fat accumulation in the liver leading to chronic fibrosis and inflammation, which can progress to cirrhosis and hepatocellular carcinoma.

Its progression is associated with fatty diets, dysregulation of metabolism and genetic predisposition. Several genes linked to NASH development are associated with lipid droplets, including HSD17B13 which encodes, a metabolic enzyme in the lipid droplet membrane.

CN Bio’s liver-on-a-chip, cultured under a high fat stress, provides a human-relevant NASH model for characterizing drugs targeting metabolism. In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.

Join the webinar to learn how:
  • Liver disease progresses from a dysregulation of metabolism
  • Lipid metabolism differs between mice and men and the impact this has on drug development
  • Primary human NASH models can evaluate drugs that target metabolism
  • NASH models allow the quantitation of lipid droplets, metabolism and fibrosis

Speaker Information:

Heather Round Image 1-1

Dr. Heather Kay Webb Hsu
Chief Scientific Officer
Inipharm


Gareth round image
Dr. Gareth Guenigault
Lead Scientist CRO Services
CN Bio

Join the webinar to learn how:

  • Liver disease progresses from a dysregulation of metabolism
  • Lipid metabolism differs between mice and men and the impact this has on drug development
  • Primary human NASH models can evaluate drugs that target metabolism
  • NASH models allow the quantitation of lipid droplets, metabolism and fibrosis

Now Available On Demand

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.